The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s pancreatic cancer drugs market report forecasts the pancreatic cancer drugs market size to grow to $4.60 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The Pancreatic Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report

Pancreatic Cancer Drugs Market Size Forecast
The global pancreatic cancer drugs market is expected to grow from $3.72 billion in 2022 to $3.91 billion in 2023 at a compound annual growth rate (CAGR) of 5.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pancreatic cancer drugs market size is expected to grow to $4.60 billion in 2027 at a CAGR of 4.1%.

North America held the largest pancreatic cancer drugs market share, and Middle East was the fastest-growing region in 2022.

Key Pancreatic Cancer Drugs Market Driver ­– Increase In The Prevalence Of Pancreatic Cancer
For instance, according to the American Cancer Society, in 2021, around 60,430 people (28,480 women and 31,950 men) are diagnosed with pancreatic cancer and approximately 48,220 people (22,950 women and 25,270 men) died from this cancer.

Request for A Sample Of The Global Pancreatic Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2565&type=smp

Key Pancreatic Cancer Drugs Market Trend – Adopting Combination Therapy
The concept of combination therapy over monotherapy is one of the latest ongoing trends in the pancreatic cancer drugs market. Major players in the market understand that the combination of two or more drugs is a suitable way to increase the efficacy of the drugs and thus increase the rate of survival of patients being diagnosed with pancreatic cancer. Some of the companies investing in the combination therapy are Rafael Pharmaceuticals announced the initiation of the Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 (delimitate) in combination with Modified FOLFIRINOX as first-line treatment for patients with Metastatic Pancreatic Cancer and Apexigen, Inc., a clinical-stage biopharmaceutical company, announced the presentation of new clinical data on APX005M in combination therapy in patients with metastatic pancreatic cancer.

Pancreatic Cancer Drugs Market Segment
1) By Type: Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer
2) By End User: Hospitals, Clinics, Other End-Users
3) By Drugs: Afinitor, Erlotinib, Hydrochloride Everolimus, 5-FU, Flurouracil, Gemcitanine, Abraxane

Pancreatic Cancer Drugs Market Major Players and Strategies
Major players in the pancreatic cancer drugs market are Eli Lilly and Company, F. Hoffman LA Rouch, Clovis Oncology, Pfizer, Novartis AG, Amgen, Celegene Corporation, AB Science, GlaxoSmithKline and Abbvie Inc.

In April 2021, Servier, a France-based pharmaceutical company acquired Agios Pharmaceuticals for an undisclosed amount. Through this acquisition, Servier strengthens its portfolio in oncology. Agios Pharmaceuticals is a US-based drug development and pharmaceutical company including pancreatic cancer drugs.

The Pancreatic Cancer Drugs Global Market Report 2023 covers regional data on pancreatic cancer drugs market size, pancreatic cancer drugs market trends and drivers, opportunities, strategies, and pancreatic cancer drugs market competitor analysis. The countries covered in the pancreatic cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The pancreatic cancer drugs refers to the medications or drugs that are used to treat pancreatic cancer which is caused by the unrestrained growth of cells in the pancreas, thus disrupting the production of digestive juices and hormones responsible to regulate the blood sugar level in the body. This abnormal growth of cells leads to tissue lumps referred to as tumors. The presence of tumors hinders normal pancreas functioning.

View More Reports Related To The Pancreatic Cancer Drugs Market –
Skin Cancer Drugs Global Market Report 2023
Lung Cancer Drugs Global Market Report 2023
Bladder Cancer Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: